Skip to search formSkip to main contentSkip to account menu

infliximab

Known as: INF, Antibody cA2, Monoclonal, MAb cA2 
A monoclonal antibody that blocks the action of a cytokine called tumor necrosis factor alfa. It is being studied in the treatment and prevention of… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2010
Highly Cited
2010
BACKGROUND The comparative efficacy and safety of infliximab and azathioprine therapy alone or in combination for Crohn's disease… 
Highly Cited
2005
Highly Cited
2005
BACKGROUND Infliximab, a chimeric monoclonal antibody directed against tumor necrosis factor alpha, is an established treatment… 
Highly Cited
2004
Highly Cited
2004
BACKGROUND Infliximab, a monoclonal antibody against tumor necrosis factor, is an effective maintenance therapy for patients with… 
Highly Cited
2003
Highly Cited
2003
BACKGROUND Treatment with infliximab, a chimeric monoclonal IgG1 antibody against tumor necrosis factor, can result in the… 
Highly Cited
2002
Highly Cited
2001
Highly Cited
2001
Background Infliximab is a humanized antibody against tumor necrosis factor α (TNF-α) that is used in the treatment of Crohn's… 
Highly Cited
2001
Highly Cited
2001
BACKGROUND Infliximab is a humanized antibody against tumor necrosis factor alpha (TNF-alpha) that is used in the treatment of… 
Highly Cited
2000
Highly Cited
2000
BACKGROUND Neutralization of tumor necrosis factor a (TNF-alpha) for three to six months reduces the symptoms and signs of… 
Highly Cited
1999
Highly Cited
1999
BACKGROUND Enterocutaneous fistulas are a serious complication of Crohn's disease and are difficult to treat. Infliximab, a… 
Highly Cited
1997
Highly Cited
1997
Background Studies in animals and an open-label trial have suggested a role for antibodies to tumor necrosis factor…